Thus, the present study evaluated the correlation between decorin levels in the BM plasma and clinical features and treatment outcome in 121 patients with newly diagnosed multiple myeloma (NDMM) to explore the possible roles of decorin in MM. This evidence concerns the gene DCN and AL amyloidosis.